<DOC>
	<DOCNO>NCT02574078</DOCNO>
	<brief_summary>The purpose study determine whether nivolumab monotherapy combination Standard care ( SOC ) therapy provide clinical benefit ( i.e. , PFS , OS , DOR ) without unacceptable toxicity advance Non-Small Cell Lung Cancer patient .</brief_summary>
	<brief_title>A Study Nivolumab Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Epidermal Growth Factor Receptor ( EGFR ) , Anaplastic Lymphoma Kinase ( ALK ) **Please note study longer enrol patient Groups A , B , C , E .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histologically confirm locally advanced stage IV NSCLC Eastern Cooperative Oncology Group ( ECOG ) Performance status ( PS ) 02 Tumor tissue section must available biomarker evaluation Untreated active/progressing Central Nervous system ( CNS ) metastases Active , know suspected autoimmune disease Known history test positive HIV AIDS Active chronic infection hepatitis B virus hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>